OverviewSuggest Edit

Soligenix, Inc. is a research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The Company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing.
TypePublic
Founded1987
HQPrinceton, NJ, US
Websitesoligenix.com

Latest Updates

Employees (est.) (Dec 2018)14(-22%)
Revenue (FY, 2019)$4.6 M(-11%)
Share Price (Jan 2021)$1.7 (+8%)
Cybersecurity ratingAMore

Key People/Management at Soligenix

Christopher J. Schaber

Christopher J. Schaber

Chairman, President and Chief Executive Officer
R. Christopher Cavalli

R. Christopher Cavalli

Vice President, Biopharmaceutical Development
Diane L. Parks

Diane L. Parks

Director
Gregg A. Lapointe

Gregg A. Lapointe

Director
Daniel P. Ring

Daniel P. Ring

Vice President, Business Development and Strategic Planning
Adam T. Rumage

Adam T. Rumage

Vice President, Project Management & Regulatory Affairs
Show more

Soligenix Office Locations

Soligenix has an office in Princeton
Princeton, NJ, US (HQ)
29 Emmons Dr
Show all (1)

Soligenix Financials and Metrics

Soligenix Revenue

Embed Graph
View revenue for all periods
Soligenix's revenue was reported to be $4.63 m in FY, 2019
USD

Revenue (Q2, 2020)

505.3k

Gross profit (Q2, 2020)

141.9k

Gross profit margin (Q2, 2020), %

28.1%

Net income (Q2, 2020)

(2.8m)

EBIT (Q2, 2020)

(2.8m)

Market capitalization (22-Jan-2021)

54.2m

Closing stock price (22-Jan-2021)

1.7

Cash (30-Jun-2020)

11.2m

EV

43.4m
Soligenix's current market capitalization is $54.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.7m3.1m3.2m7.0m8.8m10.4m5.4m5.2m4.6m

Revenue growth, %

118%24%19%(48%)(4%)

Cost of goods sold

2.1m2.6m2.5m5.3m6.9m8.4m4.3m4.6m3.6m

Gross profit

5.6m551.5k679.9k1.7m1.9m2.0m1.1m643.7k1.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

405.8k5.8m931.6k910.6k1.4m2.8m816.3k1.1m3.9m2.6m3.2m3.0m1.3m991.0k1.8m1.1m1.7m1.4m1.1m1.5m1.3m924.6k505.3k

Cost of goods sold

349.5k655.1k556.6k616.3k761.6k743.7k527.9k245.9k629.0k1.0m2.1m527.4k816.7k3.1m2.2m2.3m2.6m1.1m677.2k1.5m978.9k1.5m1.2m927.9k1.1m965.5k829.5k363.3k

Gross profit

56.3k5.1m170.0k281.6k383.7k678.2k288.9k283.1k828.9k398.7k817.5k329.2k243.6k313.8k347.9k140.9k231.9k144.1k216.9k458.2k289.5k95.0k141.9k

Gross profit Margin, %

14%89%18%31%27%24%35%26%21%15%26%11%18%32%19%13%13%10%19%30%23%10%28%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.0m3.4m5.9m5.5m4.9m8.8m7.8m9.0m5.4m

Accounts Receivable

52.8m

Prepaid Expenses

195.8k140.7k135.4k172.9k244.3k263.3k609.7k

Current Assets

7.1m3.8m7.6m6.5m7.2m10.1m9.4m10.3m7.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

4.2m7.2m5.3m4.4m3.7m2.6m8.1m6.6m5.6m5.0m4.2m5.0m4.0m4.0m4.3m3.2m5.7m7.1m5.8m5.0m6.4m4.2m11.7m7.2m7.0m6.6m7.2m11.2m

Accounts Receivable

4.3k

Prepaid Expenses

91.6k154.7k144.0k250.0k209.5k170.8k195.0k198.1k97.6k63.5k205.5k131.5k243.5k158.2k89.5k229.1k225.6k137.5k129.1k120.6k159.2k122.9k421.0k211.5k149.7k589.1k271.9k174.5k

Current Assets

4.6m7.7m5.8m4.9m4.1m3.4m8.5m6.9m6.4m5.6m5.8m5.5m5.0m6.1m5.4m5.2m7.6m8.3m6.7m5.8m7.4m5.9m13.1m9.1m8.8m8.0m9.6m12.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.4m)(4.2m)(10.1m)(6.7m)(7.8m)(3.2m)(7.1m)(8.9m)(9.4m)

Depreciation and Amortization

226.0k230.6k230.1k245.8k247.5k89.9k68.6k44.1k54.5k

Inventories

Accounts Payable

(370.6k)(179.1k)395.8k1.5m1.4m(1.5m)382.7k1.0m2.0m
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Soligenix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Soligenix Online and Social Media Presence

Embed Graph

Soligenix News and Updates

Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has...

Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development

PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the...

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary...

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

PRINCETON, N.J., Oct. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued...

Soligenix to Present at the BIO Investor Forum

PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its...

Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of...
Show more

Soligenix Blogs

Soligenix to Present RiVax(R) Program at the 13th Annual CounterACT Network Research Symposium

Princeton, NJ – June 13, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr.… The post Soligenix to Present Ri…

Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents

PRINCETON, NJ – May 28, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix… The post Soligenix Announce…

Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results

PRINCETON, NJ – May 14, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent… The post Soligenix Announces Re…

Dr. Christopher J. Schaber’s Interview with The Wall Street Analyzer

In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer. Listen to the interview (opens in a new window) The post Dr. Christopher J. Schaber’s Interview with The Wall Street Analyzer appeared first on Soligenix.

Soligenix – Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

Company provides Q1 2019 update and guidance   Princeton, NJ – April 23, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is… The post Soligenix – Advancing t…

Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

Enrollment Sufficient to Support the Interim Efficacy Analysis Princeton, NJ – April 18, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is… The post Soligen…
Show more

Soligenix Frequently Asked Questions

  • When was Soligenix founded?

    Soligenix was founded in 1987.

  • Who are Soligenix key executives?

    Soligenix's key executives are Christopher J. Schaber, R. Christopher Cavalli and Diane L. Parks.

  • How many employees does Soligenix have?

    Soligenix has 14 employees.

  • What is Soligenix revenue?

    Latest Soligenix annual revenue is $4.6 m.

  • What is Soligenix revenue per employee?

    Latest Soligenix revenue per employee is $330.7 k.

  • Who are Soligenix competitors?

    Competitors of Soligenix include Taiwan Liposome, Gero and Virun.

  • Where is Soligenix headquarters?

    Soligenix headquarters is located at 29 Emmons Dr, Princeton.

  • Where are Soligenix offices?

    Soligenix has an office in Princeton.

  • How many offices does Soligenix have?

    Soligenix has 1 office.